ALXO (ALX Oncology Holdings) Total Assets: $160.55 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALXO ALX Oncology Holdings Inc ALXO
31 GF Score
Price $2.01
! 3 Warning Signs
View Full Analysis

What is ALX Oncology Holdings Total Assets?

ALX Oncology Holdings ALXO +1.26% 31 Total Assets is $160.55 Mil as of Jun. 2026. GuruFocus rates ALXO with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

ALX Oncology Holdings's Total Assets for the quarter that ended in Jun. 2026 was $160.55 Mil.

During the past 12 months, ALX Oncology Holdings's average Total Assets Growth Rate was -55.20% per year. During the past 3 years, the average Total Assets Growth Rate was -29.30% per year. During the past 5 years, the average Total Assets Growth Rate was 37.80% per year.

During the past 8 years, ALX Oncology Holdings's highest 3-Year average Total Assets Growth Rate was 219.40%. The lowest was -29.30%. And the median was 78.50%.

Total Assets is connected with ROA %. ALX Oncology Holdings's annualized ROA % for the quarter that ended in Jun. 2026 was -42.42%. Total Assets is also linked to Revenue through Asset Turnover. ALX Oncology Holdings's Asset Turnover for the quarter that ended in Jun. 2026 was 0.00.

ALX Oncology Holdings  (NAS:ALXO) Total Assets Explanation

Total Assets is connected with ROA %.

ALX Oncology Holdings's annualized ROA % for the quarter that ended in Jun. 2026 is

ROA %=Net Income (Q: Jun. 2026 )/( (Total Assets (Q: Mar. 2026 )+Total Assets (Q: Jun. 2026 ))/ count )
=-71.884/( (178.328+160.55)/ 2 )
=-71.884/169.439
=-42.42 %

Note: The Net Income data used here is four times the quarterly (Jun. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

ALX Oncology Holdings's Asset Turnover for the quarter that ended in Jun. 2026 is

Asset Turnover
=Revenue (Q: Jun. 2026 )/( (Total Assets (Q: Mar. 2026 )+Total Assets (Q: Jun. 2026 ))/ count )
=0/( (178.328+160.55)/ 2 )
=0/169.439
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

ALX Oncology Holdings Total Assets Related Terms

ALX Oncology Holdings Total Assets Historical Data

* Premium members only.

The historical data trend for ALX Oncology Holdings's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ALX Oncology Holdings Total Assets Chart

ALX Oncology Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial 380.18 306.49 242.55 147.78 59.05

ALX Oncology Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 95.32 82.72 59.05 178.33 160.55
ALXO
31GF Score
ALX Oncology Holdings Inc ALXO
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ALX Oncology Holdings Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

ALX Oncology Holdings's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=25.981+33.065
=59.05

ALX Oncology Holdings's Total Assets for the quarter that ended in Jun. 2026 is calculated as

Total Assets=Total Equity (Q: Jun. 2026 )+Total Liabilities (Q: Jun. 2026 )
=136.187+24.363
=160.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $160.55 Mil mean?
ALX Oncology Holdings (ALXO) has a Total Assets of $160.55 Mil as of Jun. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on ALX Oncology Holdings and its competitors.
Is ALX Oncology Holdings' Total Assets too high?
ALX Oncology Holdings' current Total Assets is $160.55 Mil. Overall, ALX Oncology Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does ALX Oncology Holdings' Total Assets compare to CYDY and BCYC?
ALX Oncology Holdings' Total Assets of $160.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on ALX Oncology Holdings and its competitors. ALX Oncology Holdings's current Total Assets is $160.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ALX Oncology Holdings stock overvalued right now?
ALX Oncology Holdings (ALXO) has a current Total Assets of $160.55 Mil. The current Total Assets is $160.55 Mil. ALX Oncology Holdings' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For ALX Oncology Holdings (ALXO), the current Total Assets is $160.55 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ALX Oncology Holdings Business Description

Address 323 Allerton Avenue, South San Francisco, CA, USA, 94080
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
31GF Score

Get the complete analysis for ALXO

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.01
Price